Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

Saeedi, Ramesh; Johns, Kevin; Fröhlich, Jiří; Bennett, Matthew T.; Bondy, Gregory P.

doi:10.1186/s12944-015-0054-x

Cited by 26 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atorvastatin and rosuvastatin, the two highest‐intensity statins, have modest interactions with ART and can be safely prescribed for PLHIV with lipid‐lowering effects similar to those for uninfected patients 19 . Addition of ezetimibe to rosuvastatin results in improved lipid indices with no adverse effects compared with dose‐increase of rosuvastatin 20 . A recent study among 7686 HIV/hepatitis C virus‐coinfected and 17 739 HIV ‐monoinfected persons showed that statin initiators had a lower risk of acute liver injury and death within 18 months compared with statin nonusers 21 .…”

Section: Discussionmentioning

confidence: 99%

Outcomes of coronary artery bypass grafting in patients with human immunodeficiency virus infection

et al. 2020

View full text Add to dashboard Cite

Background With early and effective antiretroviral therapy and improved survival for persons living with human immunodeficiency virus infection (PLHIV), this patient population now faces an increasingly elevated risk of cardiovascular disease. However, the data on outcomes after coronary artery bypass grafting (CABG) for revascularization of coronary artery disease (CAD) in HIV+ patients is limited. Methods We conducted a retrospective analysis of 16 patients undergoing isolated CABG at the Medical University of Vienna from 2005 to 2018, who were HIV+ on admission. The primary endpoint of the study was survival. Secondary endpoints included the components of major adverse cardiac and cerebrovascular events (MACCE): cardiovascular death, stroke, myocardial infarction (MI), and repeat revascularization. Results Patients were followed for a median of 49 months (range, 7‐142 months). Survival was 100% and 90% at 1 and 3 years after CABG, respectively. There were no strokes. MI and subsequent repeat revascularization were observed in two patients. Conclusion CABG provides excellent short‐ and midterm survival and freedom from MACCE in HIV+ patients with CAD requiring revascularization.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of coronary artery bypass grafting in patients with human immunodeficiency virus infection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Most probably, the anti-HIV-1, EV1, as well as HCV action of ezetimibe is associated with depletion of cholesterol which is required for entry of these viruses into the host cells (Sainz et al, 2012). Importantly, this drug was successfully tested in combination with antiretroviral therapeutics to lower cholesterol levels in serum of HIV-infected patients (Saeedi et al, 2015;Wohl et al, 2008). The question remains whether ezetimibe alone reduces HIV titers in these patients.…”

Section: Discussionmentioning

confidence: 99%

Novel activities of safe-in-human broad-spectrum antiviral agents

et al. 2018

View full text Add to dashboard Cite

According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.

show abstract

“…Finally, 11 studies (n = 1926 participants) were eligible for the meta-analysis ( Fig. 1) [13][14][15][16][17][18][19][20][21][22][23].…”

Section: Study Selectionmentioning

confidence: 99%

Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature

et al. 2020

View full text Add to dashboard Cite

Background: The aim of this study was to compare and summarize the lipid-altering effects of combination therapy with ezetimibe and statins (E/S) and a double dose of statin (D/S) monotherapy on patients with hypercholesterolemia. Methods: We conducted search on 2 medical databases, PubMed and EMBASE to identify all relevant studies. A meta-analysis was performed to clarify the efficacy in the two groups. Only double-blind Randomized controlled study (RCTs) of efficacy evaluation in the two groups with ezetimibe and statins and a double dose of statin in participants with hypercholesterolemia that examined low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high-density lipoprotein (HDL) were included. Two reviewers extracted data from all primary studies independently. The primary data were the level of LDL-C, TC and HDL-C concentrations at the end point and are expressed as mean and standard deviation (SD). Results: A total of 11 double-blind, active or placebo-controlled studies with 1926 hypercholesterolemia adults randomized to ezetimibe 10 mg added to ongoing statins (N = 994) or statin titration (doubling) (N = 932) were pooled for the global meta-analysis. The effect size between treatment groups within individual studies was assessed by weighted mean difference (MD) using a random-or fixed-effect model. The result showed that the participants in E/S group get obvious lower LDL-C [MD =-13.14 mg/dL, 95%CI (−16.83,-9.44), p = 0.00001] and TC concentration [MD =-23.79 mg/dL, 95%CI (−38.65,-8.93), p = 0.002] from baseline to follow-up, comparing to the D/ S group. Besides, no significant between-group differences were observed for concentrations of HDL-C [MD = 0.46 mg/dL, 95%CI (− 1.14, 2.06), p = 0.57]. According to subgroup analysis, the combination of ezetimibe and atorvastatin (10 mg) [MD =-16.98 mg/dL, p < 0 .0001] or simvastatin (20 mg) [MD =-17.35 mg/dL, p < 0 .0001] showed stronger ability of reducing LDL-C than combination of ezetimibe and rosuvastatin (10 mg) [MD =-9.29 mg/dL, p = 0.05]. The efficacy of short-term (endpoint time between 6 to 16 week) and long-term (52 week) treatment in the LDL-C between two groups did not show significant differences. Besides, only participants from Asia treated with combination therapy were associated with a significant lower LDL-C concentration [MD =-14.7 mg/dL, p < 0 .0001].

show abstract

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

Cited by 26 publications

References 36 publications

Outcomes of coronary artery bypass grafting in patients with human immunodeficiency virus infection

Outcomes of coronary artery bypass grafting in patients with human immunodeficiency virus infection

Novel activities of safe-in-human broad-spectrum antiviral agents

Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature

Contact Info

Product

Resources

About